Quest Diagnostics Investments, Inc.

Focus Diagnostics, Inc.

Quest Diagnostics Infectious Disease, Inc.

Jules Chen

Michelle M Tabb

Lilly I Kong

Fan Chen

Michael Aye

Ming-Chou Lee

Mehrdad Jannatipour

Peter Lee

Raymond Huang

Kristin Ramos

Ning Lu

Maurice Exner

Huong Mai

Luca Jacky

Yin-Peng Chen

Emberlee Eleazar

The present disclosure provides methods for determining whether a patient exhibiting pertussis-like symptoms will benefit from treatment, with therapeutic agents that inhibit. These methods are based on detecting, andin a biological sample by assaying for the presence of the IS481, IS 1001, and hIS1001 target repeat elements, respectively. Kits for use in practicing the methods are also provided.

Methods for detecting

The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.

Methods for detecting norovirus

Methods for detecting Norovirus

Disclosed herein are methods and compositions for detectingandby detecting the presence of the IS481 and IS1001 genomic insertion sequences, respectively.

Bordetella detection assay

The invention provides methods and compositions for rapid, sensitive, and highly specific nucleic acid-based (e.g., DNA based) detection of a BK virus in a sample. In general, the methods involve detecting a target nucleic acid having a target sequence of a conserved region of BK viral genomes. The invention also features compositions, including primers, probes, and kits, for use in the methods of the invention.

Methods and compositions for detecting BK virus

detection assay

The present invention generally relates to a molecular test of Influenza A, Influenza B, Respiratory Syncytial Virus A, and Respiratory Syncytial Virus B in order to identify patients with a viral infection. Accordingly methods and compositions are disclosed to determine the presence or absence of a viral pathogen in a sample containing one or more target nucleic acids from the M gene of Influenza A, Influenza B, Respiratory Syncytial Virus A, and/or Respiratory Syncytial Virus B.

Multiplex detection assay for influenza and RSV viruses

Provided herein are methods for identifying the presence or absence of a target nucleic acid from a microorganism using direct amplification without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids.

Direct amplification and detection of viral and bacterial pathogens

Growing community of inventors

Walnut, CA, United States of America

Jules Chen